Condition: Breast Atypical Ductal Hyperplasia · Breast Atypical Lobular Hyperplasia · Breast Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center - Prevention Research Clinic | Tucson, Arizona, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Illinois College of Medicine - Chicago | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Withdrawn |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Case Western Reserve University | Cleveland, Ohio, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06184750